Fresh Equities
OPTHEA LIMITED

OPTHEA LIMITED

ASX:OPT

Company Information

Opthea Limited (OPT, formerly Circadian Technologies Limited) is a biologics drug developer focusing on ophthalmic disease therapies. Opthea's lead molecule is OPT-302 for the treatment of �back of the eye' disease such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT-302 is a soluble form of VEGFR-3 that acts a VEGF-C/VEGF-D 'trap'. Former Names Circadian Technologies Limited (CIR), 11/12/2015

Type

Listed Company

GICS Sub-Industry

Biotechnology

Head Office

Unit 4/650 Chapel St, South Yarra VIC 3141, Australia

Biotechnology
Health Care

Quarterly Cash Flows

The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.



Fresh Equities

Copyright © 2018 Fresh Equities. All rights reserved.

ACN 619 657 028. CAR: 001267539 of AFSL: 471379.
Archive
Support
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by Fresh Equities Pty Ltd, its representatives or any other third party regardless of whether such security, product or service is referenced on this website.